This website is a global information resource. It is intended for healthcare professionals only outside of the United States of America (US) who are interested in information on Foundation Medicine®. This site is not intended to provide medical advice and/or treatment guidance. If you are a US healthcare professional click here.

This site is produced by Roche as a partner of Roche Foundation Medicine.

Please be aware that you are leaving




Our pioneering, FDA-validated, tissue-based, comprehensive genomic profiling service for all solid tumours to help guide informed, personalised treatment decisions.1–3

What is FoundationOne®CDx?

Delivers all insights at once in a single test, thus saving tissue and time versus sequential biomarker testing1,2,6Provides insights that can help support treatment decisions and may improve clinical outcomes¥2,11–14Potentially expands your patients treatment options¥1,6–10 Reports vary according toregional differences, e.g. EU reports list EU-approvedtherapy options to supportclinical decision-making§5Clear, in-depth report providesinsights on the genomic profileof your patient, as well asassociated targeted therapiesand immunotherapies (rankedalphabetically within NCCNCategories of Preference) andrelevant clinical trials6Based on our analytically and clinically validated, FDA-approved comprehensive platform†1,5Assesses the four main classes of genomic alterations* in 324 cancer-relevant genes and reports TMB, MSI and LoH1,2A single, tissue- and time-saving testOpens possibilitiesEU reportSupports clinical decision-making Extensively validated 324 genes, TMB, MSI and LoHFDA
Genes and genomic signatures

Comprehensive assessment in a single test

FoundationOne CDx comprehensively examines the tumour genome, assessing the four main classes of genomic alterations in 324 known cancer-relevant genes, while also reporting TMB and MSI, which can help inform eligibility for immunotherapies.1,2,15─23 In addition, FoundationOne CDx reports high Loss of Heterozygosity (LoH), which may reflect if a tumour is homologous recombination deficient (HRD+) and which can help inform the use of poly-ADP ribose polymerase (PARP) inhibitors.24,25
Tumour mutational burdenBase SubstitutionsInsertions and deletionsCopy number alterationsRearrangementsMicrosatellite instabilityMSILoHTMBAnalyses324known cancer-relevant genes


Based on FDA-approved comprehensive platform

FoundationOne CDx is based on our analytically and clinically validated, FDA-approved comprehensive platform.3,4 You can be confident in the insights generated by FoundationOne CDx thanks to the review and approval of the workflow by the FDA, including analytical and clinical validation, and bioinformatics.3,4

What is the difference between analytical and clinical validation?

In-depth report

EU report includes EU-approved therapies to support clinical decision-making§5

A clear, in-depth report provides insights on your patient’s genomic profile as well as associated targeted therapies, immunotherapies and relevant clinical trials.5 Approved therapies are ranked alphabetically within NCCN therapy categories. The report also highlights important disease-relevant genes with no reportable alterations identified and genomic alterations associated with potential resistance to therapy to help rule out potentially ineffective treatment.5 Reports vary according to regional differences, e.g. EU reports list EU-approved therapy options to support clinical decision-making.§

When using different Foundation Medicine services across the patient journey, consistency of the reports aid comparison of the results.

Impact of FoundationOne CDx

Opens up treatment possibilities

FoundationOne CDx may detect clinically relevant genomic alterations missed by other tests, thereby opening up new treatment options.§6–14

Key alterations in NSCLC

Efficient testing

Saves tissue and time

FoundationOne CDx delivers all insights at once in a single test, saving tissue and time.
Single biomarker testing FoundationOne CDx Biopsy Negative for tested biomarker Biopsy Delivers all insights at once Repeat testing Negative for tested biomarker Re-biopsy due to

Order FoundationOne CDx

Experience how FoundationOne CDx can help guide informed, personalised treatment decisions. Find out more about getting started.

PD-L1 by IHC can be ordered as a supplemental test and may inform eligibility for several immunotherapies across many different cancer types.

*Base substitutions, insertions or deletions, copy number alterations and gene rearrangements.

†Clinical validation demonstrated concordance with the following companion diagnostics: cobas® EGFR Mutation Test, Ventana ALK (D5F3) CDx Assay, Vysis ALK Break-Apart FISH Probe Kit, therascreen® KRAS RGQ PCR Kit, Dako HER2 FISH PharmDx® Kit, cobas® BRAF V600 Mutation Test, THxID® BRAF kit. For more information, please see the FoundationOne®CDx Technical Information available at:

For additional information on the NCCN categories please refer to the NCCN Compendium® (

§Therapies contained in the EU version of the report may have been approved through a centralised EU procedure or a national procedure in an EU Member State.

¥Based on a concordance study with FoundationOne®. FoundationOne CDx leverages the same comprehensive genomic profiling approach and is highly concordant with FoundationOne.

EGFR, epidermal growth factor receptor; FDA, US Food and Drug Administration; FISH, fluorescence in situ hybridisation; LoH, Loss of Heterozygosity; IHC, immunohistochemistry; MSI, Microsatellite Instability; NCCN, National Comprehensive Cancer Network; NGS, next generation sequencing; NSCLC, non-small cell lung cancer; PARP, poly-ADP ribose polymerase; PD-L1, programmed cell death ligand 1; TKI, tyrosine kinase inhibitor; TMB, Tumour Mutational Burden.

Date of item: January 2022. M-IE-00000628
  1. Frampton GM et al. Nat Biotechnol 2013; 31: 1023–1031.
  2. FoundationOne®CDx Technical Specifications. Available at: (Accessed August 2021).
  3. FoundationOne®CDx FDA Approval, 2017. Available at: (Accessed August 2020).
  4. FoundationOne®CDx Clinical Validation, 2017. Available at: (Accessed August 2021).
  5. FoundationOne®CDx Sample Report. Available at: (Accessed August 2021).
  6. Drilon A et al. Clin Cancer Res 2015; 21: 3631–3639.
  7. Rankin A et al. Oncologist 2016; 21: 1306–1314.
  8. Ross JS et al. Cancer 2016; 122: 2654–2662.
  9. Suh JH et al. Oncologist 2016; 21: 684–691.
  10. Hirshfield KM et al. Oncologist 2016; 21: 1315–1325.
  11. Rozenblum AB et al. J Thorac Oncol 2017; 12: 258–268.
  12. Schwaederle M et al. Mol Cancer Ther 2016; 15: 743–752. 
  13. Wheler JJ et al. Cancer Res 2016; 76: 3690–3701. 
  14. Dhir M et al. Cancer Med 2017; 6: 195–206. 
  15. Zhao P et al. J Hematol Oncol 2019; 12: 54.
  16. Abida W et al. JAMA Oncol 2019; 5: 471–478.
  17. FDA approves pembrolizumab for first-line treatment of MSI-H/dMMR colorectal cancer. Available at: (Accessed August 2021).
  18. NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer. Version 2.2020, May 2020. Available at: (Accessed August 2020).
  19. Kok M et al. ESMO Open 2019; 4(Suppl 2): e000511.
  20. Gandara DR et al. Nat Med 2018; 24: 1441–1448.
  21. FDA approves pembrolizumab for adults and children with TMB-H solid tumors, 2020. Available at: (Accessed August 2021).
  22. Marabelle A et al. Ann Oncol. 2019;30(suppl_5):v475-v532.
  23. Yarchoan M et al. JCI Insight 2019; 4: e126908.
  24. Swisher EM et al. Lancet Oncol 2017; 18:75−87.
  25. Coleman RL et al. Lancet 2017; 390:1949−61.
  26. Merker JD et al. J Clin Oncol 2018; 36: 1631–1641.
  27. Scheerens H et al. Clin Transl Sci 2017; 10: 84–92.
  28. NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer. Version 6.2020, June 2020. Available at: (Accessed August 2020).
  29. Schrock AB et al. Clin Cancer Res 2016; 22: 3281–3285.
  30. Ali SM et al. Oncologist 2016; 6: 762–770.
  31. Pekar-Zlotin M et al. Oncologist 2015; 20: 316–322.
  32. FoundationOne®Liquid CDx Technical Specifications. Available at: (Accessed August 2021).
  33. Woodhouse, R. et al. Clinical and analytical validation of FoundationOne®Liquid CDx, a novel 324-gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin. PLoS One 2020; 15(9): e0237802.